Spotlight -

Drug Development|

Quality Systems

News|Articles|July 27, 2012

Excipient Fest Slideshow and Audio

A complete and unedited audio slideshow of the Excipient Fest roundtable on atypical visible particles

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Related Content

Christy Owings, Thermo Fisher Scientific

Data Aggregation Drives AI's Impact on Clinical Supply Chains

ByChristy Owings,Zachary Zubulake

September 10th 2026

Christy Owings, Thermo Fisher Scientific

How to Vet Importer of Record Partners for Clinical Trials

ByChristy Owings,Zachary Zubulake

September 9th 2026

Christy Owings, Thermo Fisher Scientific

Managing Global Trial Supply Risk: Expert Insights

ByChristy Owings,Zachary Zubulake

September 8th 2026

PharmTech Weekly Roundup—September 4, 2026

BySusan Haigney

September 4th 2026

The FDA clears zilganersen as the first disease-modifying Alexander disease drug, giving rare disease developers a blueprint for trial design and RNA delivery.

What an Alexander Disease Approval Means for RNA Developers

ByZachary Zubulake

September 4th 2026

Trending on Pharmaceutical Technology

Why Oral Solid Dosage Validation Is a Business Continuity Function, Not Just a Compliance Requirement

Technology Transfer: Success Drivers and Obstacles Explained

European Regulators Prepare the Pharma Industry for Future Changes as Legislation is Formalized

Managing Global Trial Supply Risk: Expert Insights

Data Aggregation Drives AI's Impact on Clinical Supply Chains